Do we pay too much for prescriptions?

October 1993
Consumer Reports;Oct93, Vol. 58 Issue 10, p668
Product Review
Examines reasons why prescription drugs are priced highly. Pharmaceutical industry as first targets of health-care reform; Price raising during the 1980s; Profits earned by drug companies; Profits as necessary to attract capital for research and development; Price decisions as within the framework of patent law; Concept of price regulation. INSET: Where your prescription dollars go..


Related Articles

  • Perspectives On The Pharmaceutical Industry. Reinhardt, Uwe E. // Health Affairs;2001 A Primer, p128 

    Characterizes the pharmaceutical industry in the United States. Cost structure of the industry; Effect of drug spending on the economy; Drug spending as a percentage of gross domestic product; Pharmaceutical profits as a source of cost containment; Cost sharing by patients; Price discrimination.

  • Gov't to delay drug price rises. Csonka, Agnes // Budapest Business Journal;06/10/2002, Vol. 10 Issue 27, p4 

    Reports on the Hungarian government's plan of delaying a proposed price increase in prescription drugs receiving state subsidies by six months. Price increase for National Health Fund Administration-subsidized medications by an average of 5 percent; Plans to hike the prices of over-the-counter...

  • Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Ioannides-Demos, L.L.; Ibrahim, J.E.; McNeil, J.J.; Ioannides-Demos, Lisa L; Ibrahim, Joseph E; McNeil, John J // PharmacoEconomics;2002, Vol. 20 Issue 9, p577 

    Pharmaceutical expenditure is rising more rapidly than the general inflation rate in most advanced countries. One strategy that has been introduced to control pharmaceutical costs is reference-based pricing (RBP). Its potential is restricted to those specific segments of the drug market where...

  • Prescription market booms with volume growth accelerating. Roller, Kim // Drug Store News;5/22/2000, Vol. 22 Issue 7, p51 

    Focuses on the retail drug prescription market in 1999 in the United States. Market share of chain drug stores; Increase in mail-order sales; Continued increase in prescription volume; Price increase for branded pharmaceuticals.

  • Industry unwilling to give an inch to gain a mile. Tosh, Mark // Drug Store News;8/12/2002, Vol. 24 Issue 10, p14 

    Comments on the unwillingness of the U.S. pharmaceutical industry to compromise in order to support the legislation that would provide prescription drug benefit under Medicare. Concerns of drug makers on price controls; Outlook of community pharmacy chains on the mail ordering of drugs.

  • Drug firms shuffle Rx discount cards. Ukens, Carol // Drug Topics;5/6/2002, Vol. 146 Issue 9, p26 

    Reports on the Together Rx prescription drug discount card offered by pharmaceutical companies in the U.S. Pharmaceutical companies that offer the discount card; Information on the amount of discount offered by the card; Difference of the Together Rx card from other prescription drug discount...

  • MAINE'S PRESCRIPTION DRUG PLAN: A LOOK INTO THE CONTROVERSY. Phelps, Whitney Magee // Albany Law Review;2001, Vol. 65 Issue 1, p243 

    Explores Maine's attempt to provide its citizens with affordable medications and prescription drugs. Reason prescription drugs are costly to the elderly in the U.S.; Controversy surrounding Maine's solution; Details of the constitutionality of Maine's healthcare program.

  • Restrictive formularies may increase costs. Schachner, Michael // Business Insurance;3/25/96, Vol. 30 Issue 13, p3 

    Looks at the findings of a study pertaining to prescription drug formularies, report by the National Pharmaceutical Council. Details of the study Managed Care Outcomes Project; Basis of the study; Conclusion of Susan Horn, Institute for Clinical Outcomes Research.

  • THE NEXT BOGEYMAN? Gay, Verne // Brandweek;09/18/2000, Vol. 41 Issue 36, pE12 

    Focuses on the efforts of Citizens for Better Medicare (CBM) to campaign against government attempts to control prescription drug prices in the United States (U.S.). How CBM is funded by the pharmaceutical industry; Cost of the advertising and lobbying efforts of CBM in 1999; Criticisms of U.S....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics